Alan Hartford

469 total citations
21 papers, 336 citations indexed

About

Alan Hartford is a scholar working on Statistics and Probability, Management Science and Operations Research and Pharmacology. According to data from OpenAlex, Alan Hartford has authored 21 papers receiving a total of 336 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Statistics and Probability, 5 papers in Management Science and Operations Research and 3 papers in Pharmacology. Recurrent topics in Alan Hartford's work include Statistical Methods in Clinical Trials (13 papers), Optimal Experimental Design Methods (5 papers) and Statistical Methods and Bayesian Inference (4 papers). Alan Hartford is often cited by papers focused on Statistical Methods in Clinical Trials (13 papers), Optimal Experimental Design Methods (5 papers) and Statistical Methods and Bayesian Inference (4 papers). Alan Hartford collaborates with scholars based in United States, United Kingdom and Australia. Alan Hartford's co-authors include Carol A. Gotway, Marie Davidian, Jamie J. Zhao, Gail Murphy, Lida Liu, Arthur Bergman, José M. Vega, Kenneth C. Lasseter, John F. Paolini and Thomayant Prueksaritanont and has published in prestigious journals such as IEEE Transactions on Electron Devices, Computational Statistics & Data Analysis and The Journal of Clinical Pharmacology.

In The Last Decade

Alan Hartford

20 papers receiving 313 citations

Peers

Countries citing papers authored by Alan Hartford

Since Specialization

Citations

This map shows the geographic impact of Alan Hartford's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alan Hartford with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alan Hartford more than expected).

Fields of papers citing papers by Alan Hartford

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alan Hartford. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alan Hartford. The network helps show where Alan Hartford may publish in the future.

Co-authorship network of co-authors of Alan Hartford

This figure shows the co-authorship network connecting the top 25 collaborators of Alan Hartford. A scholar is included among the top collaborators of Alan Hartford based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alan Hartford. Alan Hartford is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension 2023 ·EClinicalMedicine ·Steve Vucic, Parvathi Menon, William Huynh, Colin Mahoney, Karen S. Ho, Alan Hartford, (unknown), (unknown), (unknown), (unknown), Robert Glanzman, (unknown), Matthew C. Kiernan	30
2	Using the Bayesian detection of potential risk using inference on blinded safety data (BDRIBS) method to support the decision to refer an event for unblinded evaluation 2021 ·Pharmaceutical Statistics ·Brian Waterhouse, Alan Hartford, Saurabh Mukhopadhyay, Ryan Ferguson, Barbara A. Hendrickson	3
3	Adaptive Designs: Results of 2016 Survey on Perception and Use 2020 ·Therapeutic Innovation & Regulatory Science ·Alan Hartford, (unknown), (unknown), E. Kathryn Miller, Alun Bedding, Silke Jörgens, Lingyun Liu, Li Chen, Caroline Morgan	10
4	A model-based approach for simulating adaptive clinical studies with surrogate endpoints used for interim decision-making 2020 ·Contemporary Clinical Trials Communications ·(unknown), Alan Hartford, Jun Zhao	6
5	Modified Goldilocks Design with strict type I error control in confirmatory clinical trials 2020 ·Journal of Biopharmaceutical Statistics ·Tianyu Zhan, (unknown), Alan Hartford, Saurabh Mukhopadhyay	2
6	Optimizing Graphical Procedures for Multiplicity Control in a Confirmatory Clinical Trial via Deep Learning 2019 ·arXiv (Cornell University) ·Tianyu Zhan, Alan Hartford, Jian Kang, Walter Offen	6
7	Simulation Practices for Adaptive Trial Designs in Drug and Device Development 2019 ·Statistics in Biopharmaceutical Research ·Cristiana Mayer, Inna Perevozskaya, Sergei Leonov, Vladimir Dragalin, Yili Pritchett, Alun Bedding, Alan Hartford, (unknown), (unknown)	15
8	Adaptive Designs: Results of 2016 Survey on Perception and Use 2018 ·Therapeutic Innovation & Regulatory Science ·Alan Hartford, (unknown), (unknown), (unknown), Alun Bedding, Silke Jörgens, Lingyun Liu, Li Chen, Caroline Morgan	9
9	Dose-ranging design and analysis methods to identify the minimum effective dose (MED) 2017 ·Contemporary Clinical Trials ·Yijie Zhou, Su Chen, Danielle Sullivan, Yihan Li, (unknown), Wangang Xie, (unknown), Yuanyuan Tang, Li Wang, Alan Hartford, (unknown)	7
10	A Bayesian Approach for PK/PD Modeling with PD Data Below Limit of Quantification 2012 ·Journal of Biopharmaceutical Statistics ·(unknown), Alan Hartford, Kuenhi Tsai	8
11	Bioequivalence of the 4‐mg Oral Granules and Chewable Tablet Formulations of Montelukast 2010 ·PubMed ·Barbara Knorr, Alan Hartford, Xiujiang Li, Amy Y. Yang, Gertrude Noonan, Elizabeth Migoya	7
12	Development of a Population Pharmacokinetic Model for Taranabant, a Cannibinoid-1 Receptor Inverse Agonist 2010 ·The AAPS Journal ·Xiujiang Li, Jace Nielsen, Brenda Cirincione, Hankun Li, Carol Addy, John A. Wagner, Alan Hartford, Ngozi Erondu, Ira Gantz, (unknown), Julie A. Stone	5
13	Fitting Compartmental Models to Multiple Dose Pharmacokinetic Data using SAS ® PROC NLMIXED 2009 ·Jing Su, Peng Sun, Xiaodong Li, Alan Hartford	1
14	The Effect of Etoricoxib on the Pharmacodynamics and Pharmacokinetics of Warfarin 2007 ·The Journal of Clinical Pharmacology ·Jules I. Schwartz, Nancy Agrawal, Alan Hartford, Josée Côté, Thomas L. Hunt, René Verbesselt, (unknown), Keith Gottesdiener	12
15	Pharmacokinetics of Montelukast in Asthmatic Patients 6 to 24 Months Old 2004 ·The Journal of Clinical Pharmacology ·Elizabeth Migoya, Gregory L. Kearns, Alan Hartford, Jamie J. Zhao, Janet van Adelsberg, Carol A. Tozzi, Barbara Knorr, Paul Deutsch	34
16	Simvastatin Does Not Have a Clinically Significant Pharmacokinetic Interaction With Fenofibrate in Humans 2004 ·The Journal of Clinical Pharmacology ·Arthur Bergman, Gail Murphy, Joanne Burke, Jamie J. Zhao, (unknown), Lida Liu, Kenneth C. Lasseter, Weili He, Thomayant Prueksaritanont, Yue Qiu, Alan Hartford, José M. Vega, John F. Paolini	75
17	Consequences of misspecifying assumptions in nonlinear mixed effects models 2000 ·Computational Statistics & Data Analysis ·Alan Hartford, Marie Davidian	44
18	Computational approaches for maximum likelihood estimation for nonlinear mixed models 2000 ·NCSU Libraries Repository (North Carolina State University Libraries) ·Alan Hartford, Marie Davidian, John F. Monahan	1
19	A new device design methodology for manufacturability 1998 ·IEEE Transactions on Electron Devices ·Jeng‐Ping Lu, W. C. Holton, (unknown), (unknown), K. W. Kim, Alan Hartford, (unknown), (unknown), M. A. Littlejohn	4
20	Geostatistical Methods for Incorporating Auxiliary Information in the Prediction of Spatial Variables 1996 ·Journal of Agricultural Biological and Environmental Statistics ·Carol A. Gotway, Alan Hartford	43

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact